Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Reshaping Crohn's Disease Market: Epidemiology Study, Drug Insights, Clinical Trials Pipeline Analysis, and Regulatory Consulting | Disease Landscape Insights

This image opens in the lightbox

News provided by

Disease Landscape Insights

02 Oct, 2023, 09:30 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Oct. 2, 2023 /PRNewswire/ -- Crohn's Disease has emerged as formidable enigma in the vast landscape of gastrointestinal disease. As per a data released by the NIH, this disease accounts for a death rate of nearly 25% to 40%. This life threating inflammatory bowel disease causes unimaginable damage to various parts of the digestive system. The effective management of this ailment has been a crucial need of the hour.

Crohn's disease is a type of an irritable bowel syndrome (ibd disease) caused by inflammation of the lining of our digestive tract. It largely affects the small intestine along with the beginning of the large intestine (colon). It causes significant damage to other parts of the digestive system. This disease may also result in ileitis, inflammation of the ileum, which is the last part of the small intestine before it connects to the large intestine (colon). It is a lifelong condition characterized by the occurrence of numerous symptoms. There is no specific medicine to treat this disease but with rigorous research activities significant treatment therapeutics have been introduced to deal with the symptoms and enhance a patient's quality of life.

Disease Landscape Insights has been offering healthcare consulting services to the industry participants in the form of stakeholders, pharma companies, medical research firms, healthcare organizations, and biotech firms, among others. Its primary aim is to empower them with crucial disease insights which can help them solidify their position. They further rely on DLI's assistance in terms of price reimbursement, market access, clinical trial management, regulatory guideline adherence, and drug development endeavours.

Price and Market Access

Crohn's Disease- A threat to public health

This disease has been affecting millions of lives across the globe, thereby presenting severe challenges to the healthcare authorities. The exact crohn's disease cause is yet to be fully understood but genetic defects, exposure to environmental toxins, unhealthy dietary habits, immune system dysfunction, along with excessive smoking and high alcohol intake are some of factors triggering the onset of this ailment.

Major crohns disease symptoms include abdominal pain, diarrhea, constipation, weight loss, joint pain, fever, loss of appetite, mouth sores, and fatigue, among others. The symptoms may vary from person to person typically characterized by periods of active symptoms (flare-ups) and periods of remission when symptoms improve or disappear.

Diagnosis and treatment

The diagnostic landscape of this disease may be quite complicated. Many of Crohn's disease symptoms resemble to that of ailments such as ulcerative colitis, pancreatitis, and celiac disease, among others. In fact, the similarity between Crohn's and colitis may pose significant diagnostic challenges for the concerned healthcare providers.

Here are some of the most effective Crohn's disease detection methods-

Blood tests- Blood tests can accurately identify markers of inflammation, anemia, and other potential signs of Crohn's disease.

Stool tests- By examining the stool of the potential patients, physicians can check for signs of infection or inflammation in the digestive tract.

Imaging studies- CT scan, MRI, and endoscopy can help doctors get clear visuals of the digestive track, helping them to identify signs of inflammation and other damage.

Biopsy- If an endoscopy is performed, tissue samples (biopsies) may be taken for microscopic examination to confirm the presence of inflammation characteristic of Crohn's disease.

Apart from that physical examination, medical history assessment, and capsule endoscopy, among others are also recommended for effective disease diagnosis.

Learn More About the FDA NDA & BLA Approval (NME) Drugs for Crohn's Disease @

https://www.diseaselandscape.com/requestsample/postid/87

When it comes to Crohn's disease or overall ibd disease treatment, R&D activities are underway to develop the most advanced drugs or therapies. Although many players have already introduced highly impactful treatment therapeutics that can alleviate the symptoms of this disorder and save the lives of many. Notably, the FDA and EMA approved indications for Crohn's disease include the use of several biologic therapies to manage inflammation and symptoms.

 Some of the most effective Crohn's disease treatment solutions are anti-inflammatory drugs, biologic therapies, immunosuppressants, corticosteroids, antibiotics, anti-diarrheal medications, and pain relievers, among others.                

Clinical Trials, Product Launch, and Post Launch Scenario

DLI supports the collection, integration, and analysis of diverse data sources in clinical trials. It helps researchers in treatment gaps identification by comprehensively assessing patient data, including genetic information, biomarkers, and treatment responses. This data-driven approach enhances the precision and efficiency of clinical trial feasibility analysis, helping researchers determine whether a potential therapy is likely to address the identified treatment gaps. It helps players in their product portfolio extension activities. It lets pharma companies identify the lucrative opportunities for developing new therapies or expanding the indications of existing ones, filling gaps in treatment options for different patient populations

In terms of drug launch strategies, DLI continues to play an indispensable role. The increased disease burden has created the need for effective drugs and therapies. DLI through its pharma consulting services, offers great help to the biotech and pharmaceutical organizations in their product launch phase. It supports market access strategy development by providing real-world evidence and insights derived from data integration. This enables companies to tailor their launch strategies, including pricing, distribution, and patient access programs, to effectively address the specific needs of patients and healthcare providers.

Discover More About Pricing and Reimbursement, Epidemiology Study, and Healthcare @

https://www.diseaselandscape.com/downloadsample/postid/87

Coming to post launch scenario, DLI helps players with the accurate collection and analysis of real-world data through its post launch services. It enables various healthcare companies to o monitor treatment outcomes, assess the effectiveness of therapies, and adjust market access strategies accordingly. By leveraging this data-driven approach, pharmaceutical companies can stay agile and responsive to evolving treatment gaps, ensuring ongoing optimization of Crohn's disease management.

Summing Up:

Crohn's disease is a devastating gastrointestinal disease affecting a large part of the world's population. It may occur at any age group and is known to last a lifetime. The symptoms differ from person to person depending on the severity of the disease. A wide range of drugs and therapies have been developed to aid Crohn's disease management. DLI serves as a foundational element in addressing treatment gaps, enhancing clinical trial assessment, supporting new product launches, extending product portfolios, and refining market access strategies throughout the entire lifecycle of Crohn's disease treatments. This data-driven approach is essential for improving patient outcomes and delivering more tailored solutions for individuals living with this condition.

Browse Through More Autoimmune Diseases Research Reports.

Related Report:

Insights and Trends in the Global Landscape of Lung Cancer Services

The symptoms, transmission, and precautions of Monkeypox

The Myths of Pneumonia: Symptoms, Causes, and Prevention Methods

Navigating the Complex Autoimmune Disorder of Lupus

Ringworm Comprehensive Guide: Symptoms, Causes, and Treatment

Diverticulitis: A Complete Guide to the Symptoms, Causes, and Treatments

When it comes to strategic Diabetes Disease consultancy, some of the areas we assist you understand include Regulatory Insights, Disease Landscape, and Market Access Expertise.

Find treatments for HPV illness using specialized market entry strategies. FDA/EMA insights and clinical trial advice. Examine right away!

Learn about specific approaches to Pancreatic Cancer Disease market access, pricing, and reimbursement. Learn about market research and clinical trials. Change your business immediately.

Learn about KOLs, the FDA, epidemiology, price reimbursement, and more in this market report on Anemia Disease. Your trustworthy source for info on anemia. Examine right away!

Addressing Ethical Considerations: Insights & Strategies: Investigating AI's Potential to Transform Radiology: Applications AI in Medical Imagingm

Addressing Ethical Considerations: Insights & Strategies for AI in Healthcare

Top cancer-related causes of death

Paxlovid is recognized as a COVID-19 Breakthrough Therapy with Emergency Use Authorization.

The Top 5 Monkeypox Research Companies and Monkeypox

How Technology is Revolutionizing the Drug Discovery Industry

Treatment, Research, and Leading Companies dealing with lung cancer

Money Is Important: Boosting Clinical Trial Revenue Strategies by Resolving CRO Issues

Dry Eye Disease Is Miebo Treating

About Disease Landscape:  

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us:  

Disease Landscape Insights LLP 
6th Floor, Sr No.207, Office A H 6070 Phase 1 
Solitaire Business Hub, Viman Nagar 
Pune, Maharashtra, 411014 
Email: ajay@diseaselandscape.com  
Email: vishal@diseaselandscape.com  
Sales: +44-2038074155
Asia Office: +917447409162
Blog: https://www.diseaselandscape.com/blogs  
Case Study: https://www.diseaselandscape.com/casestudies   
Pharma consulting Services 
Follow Us: LinkedIn | Twitter | Facebook

Logo: https://mma.prnewswire.com/media/2217060/Disease_Landscape_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.